New PhIII data for Stelara and IV Simponi back expansion of Janssen's arthritis franchise
This article was originally published in Scrip
Executive Summary
Janssen Research & Development will present data at the American College of Rheumatology (ACR) Scientific Sessions in Washington, DC that could play a role in expanding the Johnson & Johnson subsidiary's arthritis franchise with a new indication for Stelara (ustekinumab) and an intravenous version of Simponi (golimumab).